Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy

Annals of Surgical Oncology

Volumn 15, Issue 11, 2008, Pages 3157-3168

  Takano, Shigetsugu ^a   Togawa, Akira ^a   Yoshitomi, Hideyuki ^a   Shida, Takashi ^a   Kimura, Fumio ^a   Shimizu, Hiroaki ^a   Yoshidome, Hiroyuki ^a   Ohtsuka, Masayuki ^a   Kato, Atsushi ^a   Tomonaga, Takeshi ^a   Nomura, Fumio ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Annexin II; Gemcitabine; Pancreatic cancer; Prognosis; Resistance; Tailor made therapy

Indexed keywords

GEMCITABINE; LIPOCORTIN 2; SMALL INTERFERING RNA;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREAS CELL; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; STAINING; SURGICAL PATIENT; TWO DIMENSIONAL GEL ELECTROPHORESIS; WILD TYPE;

ADENOCARCINOMA; AGED; ANNEXIN A2; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, PANCREATIC DUCTAL; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 55149113850     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0061-5     Document Type: Article

References (45)

1. N Bardeesy RA Depinho 2002 Pancreatic cancer biology and genetics Nature Rev 2 897 909
2. RH Janes JE Niederhuber JS Chmiel 1996 National pattern of care for pancreatic cancer: results of a survey by the commission on cancer Ann Surg 223 261 72
3. T Thigpen 2006 The role of gemcitabine in first-line treatment of advanced ovarian carcinoma Semin Oncol 33 S26 32
4. PA Bunn Jr K Kelly 1998 New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions Clin Cancer Res 4 1087 100
5. J Carmichael 1998 The role of gemcitabine in the treatment of other tumours Br J Cancer 78 21 5
6. HA Burris MJ Moore J Anderson 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 13
7. DA Richards 2005 Chemotherapeutic gemcitabine doublets in pancreatic carcinoma Semin Oncol 32 S9 S13
8. MJ Moore D Goldstein J Hamm 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1942 52
9. V Giroux J Iovanna JC Dagorn 2006 Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance FASEB J 20 1982 91
10. V Sebastiani F Ricci B Rubio-Viquiera 2006 Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival Clin Cancer Res 12 2492 7
11. M Oh-Ishi M Satoh T Maeda 2000 Preparative two-dimensional gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins Electrophoresis 21 1653 69
12. T Tomonaga K Matsushita S Yamaguchi 2004 Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis Clin Cancer Res 10 2007 14
13. T Nishimori T Tomonaga K Matsushita 2006 Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin Proteomics 6 1011 8
14. A Togawa H Ito F Kimura 2003 Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-A on the resistant cell line Pancreas 27 220 4
15. E Ortiz-Zapatar S Peiro O Roda 2007 Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2 Am J Pathol 170 1573 84
16. S Takano H Yoshitomi A Togawa 2008 Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells Oncogene 27 2810 22
17. AC Wolff MH Hammond JN Schwartz 2007 American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 45
18. S Isaji Y Kawarada S Uemoto 2004 Classification of pancreatic cancer: comparison of Japanese and UICC classifications Pancreas 28 231 4
19. Sobin LH, Wittekind Ch, eds. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours, 6th edition. New York: John Wiley & Sons, Inc., 2002
20. M Bergenfeldt M Albertsson 2006 Current state of adjuvant therapy in resected pancreatic adenocarcinoma Acta Oncol 45 124 35
21. JP Neoptolemos DD Stocken JA Dunn 2001 (European Study Group for Pancreatic Cancer) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial Ann Surg 234 758 68
22. H Oettle S Post P Neuhaus 2007 Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267 7
23. MR Crompton SE Moss MJ Crumpton 1988 Diversity in the lipocortin/calpactin family Cell 55 1 3
24. 2+-dependent phospholipid (and membrane) binding proteins Biochemistry 27 6645 53
25. GM Cesarman CA Guevara KA Hajjar 1994 An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation J Biol Chem 269 21198 203
26. JS Menell GM Cesarman AT Jacovina 1999 Annexin II and bleeding in acute leukemia N Engl J Med 340 994 1004
27. D Massey-Harroche N Mayran S Maroux 1998 Polarized localizations of Annexin I, II, VI, and XIII in epithelial cells of intestinal, hepatic and pancreatic tissues J Cell Sci 111 3007 15
28. C Brownstein AB Deora AT Jacovina 2004 Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced by macrophages Blood 103 317 24
29. KA Hajjar S Krishnan 1999 Annexin II; a mediator of the plasmin/plasminogen activator system Trends Cardiovasc Med 9 128 38
30. KA Hajjar JS Menell 1997 Annexin II; a novel mediator of cell surface plasmin generation Ann N Y Acad Sci 811 337 49
31. BJ Roseman A Bollen K Lamborn 1994 Annexin II marks astrocytic brain tumors of high histologic grade Oncol Res 6 561 7
32. SJ Nygaard HK Haugland EK Kristoffersen 1998 Expression of annexin II in glioma cell lines and in brain tumor biopsies J Neurooncol 38 11 8
33. K Emoto Y Yamada H Sawada 2001 Annexin II overexpression correlates with stromal Tenascin-C overexpression; a prognostic marker in colorectal carcinoma Cancer 92 1419 26
34. K Emoto H Sawada Y Yamada 2001 Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma Anticancer Res 21 1339 46
35. SP Cole MJ Pinkoski G Bhardwaj 1992 Elevated expression of Annexin II (Lipocortin II, P36) in a multidrug resistant small cell lung cancer cell line Br J Cancer 65 498 502
36. R Schwartz-Albiez K Koretz P Moller 1993 Differential expression of annexins I and II in normal and malignant human mammary epithelial cells Differentiation 52 229 37
37. M Frohlich P Motte K Galvin 1990 Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma Mol Cell Biol 10 3216 23
38. JK Vishwanatha Y Chiang KD Kumble 1993 Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers Carcinogenesis 14 2575 9
39. KD Kumble M Hirota PM Pour 1992 Enhanced level of Annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts Cancer Res 52 163 7
40. I Esposito R Penzel M Chaib-Harrireche 2006 Tenascin C and annexin II expression in the process of pancreatic carcinogenesis J Pathol 208 673 85
41. R Chen EC Yi S Donohoe 2005 Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape Gastroenterology 129 1187 97
42. VM Diaz J Planaguma TM Thomson 2002 Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells Gastroenterology 122 806 19
43. VM Diaz M Hurtado TM Thomson 2004 Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro Gut 53 993 1000
44. S Chuthapisith R Layfield ID Kerr 2007 Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs Int J Oncol 30 1545 51
45. Y Huang Y Jin CH Yan 2008 Involvement of Annexin A2 in p53 induced apoptosis in lung cancer Mol Cell Biochem 309 117 23